NO930713L - In vivo avgivelse av aktive faktorer ved ko-dyrkete celleimplantater - Google Patents

In vivo avgivelse av aktive faktorer ved ko-dyrkete celleimplantater

Info

Publication number
NO930713L
NO930713L NO93930713A NO930713A NO930713L NO 930713 L NO930713 L NO 930713L NO 93930713 A NO93930713 A NO 93930713A NO 930713 A NO930713 A NO 930713A NO 930713 L NO930713 L NO 930713L
Authority
NO
Norway
Prior art keywords
active factor
culture
source
vivo release
reinforcing substance
Prior art date
Application number
NO93930713A
Other languages
English (en)
Norwegian (no)
Other versions
NO930713D0 (no
Inventor
Patrick Aebischer
Shelley R Winn
Original Assignee
Univ Brown Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Brown Res Found filed Critical Univ Brown Res Found
Publication of NO930713D0 publication Critical patent/NO930713D0/no
Publication of NO930713L publication Critical patent/NO930713L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/022—Artificial gland structures using bioreactors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0012—Cell encapsulation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0613—Cells from endocrine organs
    • C12N5/0614—Adrenal gland
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0687—Skull, cranium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0693—Brain, cerebrum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/70—Polysaccharides
    • C12N2533/74—Alginate

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
NO93930713A 1991-06-28 1993-02-26 In vivo avgivelse av aktive faktorer ved ko-dyrkete celleimplantater NO930713L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/722,894 US5182111A (en) 1987-11-17 1991-06-28 In vivo delivery of active factors by co-cultured cell implants
PCT/US1992/005390 WO1993000439A1 (en) 1991-06-28 1992-06-25 In vivo delivery of active factors by co-cultured cell implants

Publications (2)

Publication Number Publication Date
NO930713D0 NO930713D0 (no) 1993-02-26
NO930713L true NO930713L (no) 1993-04-23

Family

ID=24903864

Family Applications (1)

Application Number Title Priority Date Filing Date
NO93930713A NO930713L (no) 1991-06-28 1993-02-26 In vivo avgivelse av aktive faktorer ved ko-dyrkete celleimplantater

Country Status (15)

Country Link
US (1) US5182111A (de)
EP (1) EP0547203B1 (de)
JP (1) JPH06502080A (de)
KR (1) KR930701612A (de)
AT (1) ATE157399T1 (de)
AU (1) AU652071B2 (de)
CA (1) CA2090719C (de)
DE (1) DE69221837T2 (de)
DK (1) DK0547203T3 (de)
ES (1) ES2108125T3 (de)
FI (1) FI930883A7 (de)
GR (1) GR3025454T3 (de)
NO (1) NO930713L (de)
SG (1) SG48765A1 (de)
WO (1) WO1993000439A1 (de)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5487739A (en) * 1987-11-17 1996-01-30 Brown University Research Foundation Implantable therapy systems and methods
US5871472A (en) * 1987-11-17 1999-02-16 Brown University Research Foundation Planting devices for the focal release of neuroinhibitory compounds
US6187572B1 (en) 1990-04-16 2001-02-13 Baxter International Inc. Method of inactivation of viral and bacterial blood contaminants
US5418130A (en) 1990-04-16 1995-05-23 Cryopharm Corporation Method of inactivation of viral and bacterial blood contaminants
FI923023A7 (fi) * 1990-10-31 1992-06-29 Baxter Int Lähellään tapahtuvan verisuonittumisen aikaansaava istutemateriaali
US5314471A (en) * 1991-07-24 1994-05-24 Baxter International Inc. Tissue inplant systems and methods for sustaining viable high cell densities within a host
US5344454A (en) * 1991-07-24 1994-09-06 Baxter International Inc. Closed porous chambers for implanting tissue in a host
ATE156344T1 (de) * 1991-04-25 1997-08-15 Univ Brown Res Found Implantierbare, biokompatible immunisolator- trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte
US5800829A (en) * 1991-04-25 1998-09-01 Brown University Research Foundation Methods for coextruding immunoisolatory implantable vehicles with a biocompatible jacket and a biocompatible matrix core
US5980885A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. Growth factor-induced proliferation of neural precursor cells in vivo
US6773458B1 (en) 1991-07-24 2004-08-10 Baxter International Inc. Angiogenic tissue implant systems and methods
US5453278A (en) * 1991-07-24 1995-09-26 Baxter International Inc. Laminated barriers for tissue implants
US6204240B1 (en) * 1991-11-22 2001-03-20 Genentech, Inc. TGF-β1 to improve neural outcome
US5955095A (en) * 1992-04-22 1999-09-21 Brown University Research Foundation Microporous macrocapsules
WO1994010950A1 (en) * 1992-11-16 1994-05-26 Brown University Research Foundation Microporous macrocapsules
CA2137275A1 (en) * 1992-06-03 1993-12-09 Richard L. Eckert Bandage for continuous application of biologicals
CA2163264A1 (en) * 1993-06-02 1994-12-08 Richard L. Eckert Bandage for continuous application of biologicals
NZ269041A (en) * 1993-06-23 1998-02-26 Univ Brown Res Found Implantable encapsulation device having a cell-tight dry seal at an opening thereof
WO1995004521A1 (en) 1993-08-10 1995-02-16 W.L. Gore & Associates, Inc. Cell encapsulating device
SG48813A1 (en) * 1993-08-12 1998-05-18 Cytotherapeutics Inc Improved composition and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
US5908623A (en) 1993-08-12 1999-06-01 Cytotherapeutics, Inc. Compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
US5550050A (en) * 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US5795790A (en) * 1994-07-20 1998-08-18 Cytotherapeutics, Inc. Method for controlling proliferation and differentiation of cells encapsulated within bioartificial organs
US5935849A (en) * 1994-07-20 1999-08-10 Cytotherapeutics, Inc. Methods and compositions of growth control for cells encapsulated within bioartificial organs
DE4426315C1 (de) * 1994-07-25 1996-03-21 Gore W L & Ass Gmbh Membran zur Regeneration von Körpergeweben und Verwendung der Membran als Wundabdeckung und Hautersatz
FR2724320B1 (fr) * 1994-09-13 1996-12-20 Transgene Sa Nouvel implant pour le traitement des maladies acquises
US5916790A (en) * 1995-03-03 1999-06-29 Metabolex, Inc. Encapsulation compositions, and methods
US5681740A (en) * 1995-06-05 1997-10-28 Cytotherapeutics, Inc. Apparatus and method for storage and transporation of bioartificial organs
US5704910A (en) 1995-06-05 1998-01-06 Nephros Therapeutics, Inc. Implantable device and use therefor
US5837234A (en) * 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
WO1996039993A1 (en) 1995-06-07 1996-12-19 Gore Hybrid Technologies, Inc. An implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein
US6107102A (en) * 1995-06-07 2000-08-22 Regents Of The University Of California Therapeutic microdevices and methods of making and using same
WO1997010807A1 (en) * 1995-09-22 1997-03-27 Gore Hybrid Technologies, Inc. Improved cell encapsulation device
US5855613A (en) * 1995-10-13 1999-01-05 Islet Sheet Medical, Inc. Retrievable bioartificial implants having dimensions allowing rapid diffusion of oxygen and rapid biological response to physiological change
EP0955948B1 (de) * 1995-10-26 2005-06-15 Paul P. Latta Induktion von immunologischer toleranz
US5869041A (en) 1996-01-12 1999-02-09 The Miriam Hospital Delivery of bioactive compounds to an organism
US5792110A (en) * 1996-06-26 1998-08-11 Cunningham; Miles G. Systems and methods for delivering therapeutic agents to selected sites in a subject
US6277820B1 (en) 1998-04-09 2001-08-21 Genentech, Inc. Method of dopaminergic and serotonergic neuron formation from neuroprogenitor cells
US6206914B1 (en) 1998-04-30 2001-03-27 Medtronic, Inc. Implantable system with drug-eluting cells for on-demand local drug delivery
DE69915235T2 (de) * 1998-04-30 2005-04-14 Medtronic, Inc., Minneapolis Implantierbares system, das medikamente freisetzende zellen enthält, für eine bedarfsgerechte, lokale verabreichung von medikamenten
US7399751B2 (en) * 1999-11-04 2008-07-15 Sertoli Technologies, Inc. Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells
CN1235027A (zh) * 1999-06-16 1999-11-17 薛毅珑 用于治疗疼痛的微囊化牛肾上腺髓质嗜铬细胞药物
WO2001013119A1 (en) 1999-08-17 2001-02-22 Luminex Corporation Encapsulation of fluorescent particles
AU2002241538A1 (en) * 2000-12-01 2002-07-24 Nephros Therapeutics, Inc. Intrasvascular drug delivery device and use therefor
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US7749528B2 (en) * 2001-08-29 2010-07-06 Ricardo Azevedo Pontes De Carvalho Implantable and sealable medical device for unidirectional delivery of therapeutic agents to tissues
WO2003020172A1 (en) * 2001-08-29 2003-03-13 De Carvalho Ricardo A P An implantable and sealable system for unidirectional delivery of therapeutic agents to targeted tissues
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US20050008629A1 (en) * 2002-05-08 2005-01-13 Interpore Orthopaedics, A Delaware Corporation Encapsulated AGF cells
AU2003294541A1 (en) * 2002-12-24 2004-07-22 An-Go-Gen Inc. Encapsulated cell for therapy
US8034048B2 (en) * 2003-05-05 2011-10-11 Boston Scientific Scimed, Inc. Tissue patches and related delivery systems and methods
US7416546B2 (en) * 2003-05-05 2008-08-26 Boston Scientific Scimed, Inc. Tissue patches and related delivery systems and methods
CA2531022C (en) * 2003-07-03 2014-09-09 Jannette Dufour Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants
US20050053648A1 (en) * 2003-09-08 2005-03-10 Chalmers Anne Marie Medication delivery device
EP1682063A1 (de) * 2003-10-21 2006-07-26 Ambo Innovation LLC Digestierbare und volumenanpassbare mehrmedikations-zufuhrvorrichtung
NZ551832A (en) * 2004-06-09 2010-01-29 Univ Edinburgh Neural stem cells
WO2006016238A2 (en) * 2004-08-04 2006-02-16 Applied Research Systems Ars Holding N.V. Capsules containing transfected cells, method for preparing the same and uses thereof for immunization and vaccination
WO2006034601A1 (fr) * 2004-09-27 2006-04-06 Yilong Xue Nouvelle utilisation de cellules chromaffines medullo-surrenales ou de cellules fonctionnelles de peptides
EP1883446B8 (de) * 2005-05-17 2017-11-15 Gloria Therapeutics Sarl Implantierbares therapiesystem zur behandlung eines lebewesens mit einem wirkfaktor
US8048419B2 (en) 2006-02-02 2011-11-01 Innovative Biotherapies, Inc. Extracorporeal cell-based therapeutic device and delivery system
WO2008103101A1 (en) * 2007-02-19 2008-08-28 Ticapex Ab Implant assembly
AR065720A1 (es) * 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
WO2009052425A1 (en) 2007-10-17 2009-04-23 Neuronexus Technologies Implantable device including a resorbable carrier
AU2009327485A1 (en) * 2008-06-18 2010-06-24 Cytopherx, Inc. Methods for propagation of renal precursor cells
EP2168666A1 (de) 2008-09-25 2010-03-31 Gambro Lundia AB Bestrahlte Membran für Zellexpansion
EP2168668A1 (de) 2008-09-25 2010-03-31 Gambro Lundia AB Membran für Zellexpansion
EP2168614B1 (de) 2008-09-25 2012-02-15 Gambro Lundia AB Hybride biologische künstliche Niere
EP2177603A1 (de) 2008-09-25 2010-04-21 Gambro Lundia AB Vorrichtung für Nierenzellexpansion
JP2012508584A (ja) 2008-11-14 2012-04-12 ヴィアサイト，インコーポレイテッド ヒト多能性幹細胞由来膵臓細胞のカプセル化
EP3187581A1 (de) 2008-12-23 2017-07-05 BOCO Silicon Valley, Inc. Zielpopulationen von oligodendrozyten-vorläuferzellen und verfahren zur herstellung und verwendung davon
US20110106062A1 (en) * 2009-11-05 2011-05-05 Ecole Polytechnique Federale De Lausanne System and Method For In Vivo Delivery of Antibodies and Fragments Thereof
AU2010338425B2 (en) 2009-12-21 2015-07-23 Janssen Sciences Ireland Uc Degradable removable implant for the sustained release of an active compound
US9475709B2 (en) 2010-08-25 2016-10-25 Lockheed Martin Corporation Perforated graphene deionization or desalination
US9744617B2 (en) 2014-01-31 2017-08-29 Lockheed Martin Corporation Methods for perforating multi-layer graphene through ion bombardment
US9844757B2 (en) 2014-03-12 2017-12-19 Lockheed Martin Corporation Separation membranes formed from perforated graphene and methods for use thereof
US20160067390A1 (en) * 2014-03-12 2016-03-10 Lockheed Martin Corporation Methods for in vivo and in vitro use of graphene and other two-dimensional materials
US10376845B2 (en) 2016-04-14 2019-08-13 Lockheed Martin Corporation Membranes with tunable selectivity
US9834809B2 (en) 2014-02-28 2017-12-05 Lockheed Martin Corporation Syringe for obtaining nano-sized materials for selective assays and related methods of use
US10653824B2 (en) 2012-05-25 2020-05-19 Lockheed Martin Corporation Two-dimensional materials and uses thereof
US9610546B2 (en) 2014-03-12 2017-04-04 Lockheed Martin Corporation Separation membranes formed from perforated graphene and methods for use thereof
USD720469S1 (en) 2013-03-07 2014-12-30 Viacyte, Inc. Cell encapsulation device
AU2014225352B2 (en) * 2013-03-07 2017-02-09 Viacyte, Inc. 3-dimensional large capacity cell encapsulation device assembly
TW201504140A (zh) 2013-03-12 2015-02-01 Lockheed Corp 形成具有均勻孔尺寸之多孔石墨烯之方法
US9572918B2 (en) 2013-06-21 2017-02-21 Lockheed Martin Corporation Graphene-based filter for isolating a substance from blood
CN106029596A (zh) 2014-01-31 2016-10-12 洛克希德马丁公司 采用多孔非牺牲性支撑层的二维材料形成复合结构的方法
CN105940479A (zh) 2014-01-31 2016-09-14 洛克希德马丁公司 使用宽离子场穿孔二维材料
JP2017534311A (ja) 2014-09-02 2017-11-24 ロッキード・マーチン・コーポレーション 二次元膜材料をベースとする血液透析膜および血液濾過膜、ならびにそれを用いた方法
US20170266354A1 (en) * 2014-09-04 2017-09-21 Kemijski Institut Cell-Based Device For Local Treatment With Therapeutic Protein
JP2018528144A (ja) 2015-08-05 2018-09-27 ロッキード・マーチン・コーポレーション グラフェン系材料の穿孔可能なシート
WO2017023377A1 (en) 2015-08-06 2017-02-09 Lockheed Martin Corporation Nanoparticle modification and perforation of graphene
EP3442739A4 (de) 2016-04-14 2020-03-04 Lockheed Martin Corporation Verfahren zur behandlung von graphenfolien für grossflächigen transfer mittels free-float-verfahren
EP3442786A4 (de) 2016-04-14 2020-03-18 Lockheed Martin Corporation Zweidimensionale membranstrukturen mit strömungskanälen
EP3442697A4 (de) 2016-04-14 2020-03-18 Lockheed Martin Corporation Selektive grenzflächenminderung von graphendefekten
KR20180133430A (ko) 2016-04-14 2018-12-14 록히드 마틴 코포레이션 결함 형성 또는 힐링의 인 시츄 모니터링 및 제어를 위한 방법
WO2017180134A1 (en) 2016-04-14 2017-10-19 Lockheed Martin Corporation Methods for in vivo and in vitro use of graphene and other two-dimensional materials
JP7054523B2 (ja) * 2016-06-28 2022-04-14 国立研究開発法人農業・食品産業技術総合研究機構 細胞封入用デバイス及びその使用
CA3042495A1 (en) 2016-11-10 2018-05-17 Viacyte, Inc. Pdx1 pancreatic endoderm cells in cell delivery devices and methods thereof
JP6940090B2 (ja) * 2017-03-31 2021-09-22 国立大学法人愛媛大学 微生物封入マイクロカプセル、微生物封入マイクロカプセルを含むセメント混和材料及びセメント系構造物の補修材料
AU2020256224B2 (en) * 2019-04-03 2025-09-25 Vertex Pharmaceuticals Incorporated Multicompartment macroencapsulation devices
WO2021061940A1 (en) 2019-09-27 2021-04-01 Isla Technologies, Inc. Bioartificial pancreas

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3093831A (en) * 1959-10-22 1963-06-18 Jordan Gerhard Paul Wilhelm Artificial gland
US4241187A (en) * 1979-03-27 1980-12-23 United States Of America Method and apparatus for cell and tissue culture
US4352883A (en) * 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4391909A (en) * 1979-03-28 1983-07-05 Damon Corporation Microcapsules containing viable tissue cells
NO161446C (no) * 1981-03-13 1989-08-16 Damon Biotech Inc Fremgangsmaate for dyrking av celler som er avhengige av forankring.
US4378016A (en) * 1981-07-15 1983-03-29 Biotek, Inc. Artificial endocrine gland containing hormone-producing cells
US4402694A (en) * 1981-07-16 1983-09-06 Biotek, Inc. Body cavity access device containing a hormone source
US4686098A (en) * 1984-05-14 1987-08-11 Merck & Co., Inc. Encapsulated mouse cells transformed with avian retrovirus-bovine growth hormone DNA, and a method of administering BGH in vivo
EP0213908A3 (de) * 1985-08-26 1989-03-22 Hana Biologics, Inc. Transplantierbares Kunstgewebe und Verfahren
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
KR100196062B1 (ko) * 1989-06-15 1999-06-15 로버트 에프. 게이민 세포를 성장시키기 위한 방법, 조성물 및 장치
CA2062746C (en) * 1989-06-21 1999-02-02 Patrick Aebischer Neurological therapy system

Also Published As

Publication number Publication date
FI930883L (fi) 1993-04-20
EP0547203B1 (de) 1997-08-27
GR3025454T3 (en) 1998-02-27
NO930713D0 (no) 1993-02-26
CA2090719C (en) 1996-08-20
DK0547203T3 (da) 1998-04-20
CA2090719A1 (en) 1992-12-29
US5182111A (en) 1993-01-26
AU2296192A (en) 1993-01-25
DE69221837T2 (de) 1998-03-05
EP0547203A1 (de) 1993-06-23
AU652071B2 (en) 1994-08-11
ES2108125T3 (es) 1997-12-16
KR930701612A (ko) 1993-06-12
JPH06502080A (ja) 1994-03-10
SG48765A1 (en) 1998-05-18
FI930883A0 (fi) 1993-02-26
FI930883A7 (fi) 1993-04-20
WO1993000439A1 (en) 1993-01-07
DE69221837D1 (de) 1997-10-02
ATE157399T1 (de) 1997-09-15

Similar Documents

Publication Publication Date Title
NO930713L (no) In vivo avgivelse av aktive faktorer ved ko-dyrkete celleimplantater
Kumagai et al. Clinical application of autologous cultured epithelia for the treatment of burn wounds and burn scars
Böttcher et al. Co-existence of glicentin and peptide YY in colorectal L-cells in cat and man. An electron microscopic study
Heath et al. Mouse osteoblasts synthesize collagenase in response to bone resorbing agents
KR970702737A (ko) 평면이식편의 준비와 이식방법과 이를 위한 외과용기구(Method for Preparation And Transplantation of Planar Implants And Surigical Instruments Therefor)
Kim et al. Electricity auto-generating skin patch promotes wound healing process by activation of mechanosensitive ion channels
DE69634828D1 (de) Auffindbare künstliche bioimplantate
Majd et al. Novel micropatterns mechanically control fibrotic reactions at the surface of silicone implants
ATE232748T1 (de) Hemmung von gefässverengungen nach eingriffen an den gefässen
ES2160116T3 (es) Modelo de equivalente de cornea producido in vitro.
DE60018044D1 (de) Neue biomaterialien
CO5580844A2 (es) Queratinocitos utilizables como sustancia biologicamente activa en el tratamiento de heridas
US20040096430A1 (en) Method and device for producing biological tissue in a growth chamber
DK0500556T3 (da) Kompleks af aktivt stof til fremstilling af biologiske dele, især organer til levende væsner; fremgangsmåde til fremstillin
YU217890A (sh) Postupak za dobijanje genetskih konstrukcija za ekspresiju nervnog faktora rasta u eukariotskim ćelijama
Moeinvaziri et al. Inner ear organoids: progress and outlook, with a focus on the vascularization
MENDE et al. Distribution of mucopolysaccharide and alkaline phosphatase in transitional epithelia
NZ506510A (en) A permanent skin replacement comprising allogenic epithelial cells cultured in vitro and autologous epithelial cells
Rambo XLVI Musculoplasty: Advantages and Disadvantages
ATE191501T1 (de) Verwendung von hepatocyten-wachstumsfaktoren zur herstellung eines vermehrungssystems für hematopoietische stammzellen
NZ503372A (en) Chemical supplementation of bone by exposing bone to a therapeutic compound and applying a potential difference across the bone or tissue
ES2229729T3 (es) Un metodo para inducir la produccion de factores de crecimiento.
Teti et al. Osteoblast-osteoclast relationships in bone resorption: osteoblasts enhance osteoclast activity in a serum-free co-culture system
KR102731280B1 (ko) 다기능 상처 치유 패치
Wullstein et al. Further Observations on Application of “Plasticin” in Ear Surgery: six years of experience